Abstract
Neoadjuvant treatment is increasingly being used in patients with breast cancer. Understanding the effects of neoadjuvant agents in the perioperative setting is crucial as it can affect morbidity. Understanding how these agents should be used to maximize optimal time to surgery is crucial as delays can negatively affective cancer outcomes. This review aims to discuss the perioperative considerations surgeons should be aware of prior to scheduling surgery for patients receiving chemotherapy, endocrine therapy, chemotherapy, targeted therapy, and immunotherapy.
Original language | English (US) |
---|---|
Journal | Clinical Breast Cancer |
DOIs | |
State | Accepted/In press - 2025 |
Keywords
- Neoadjuvant therapy
- Perioperative
- Surgery
- Systemic therapy
- Time to surgery
ASJC Scopus subject areas
- Oncology
- Cancer Research